id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-P-7033-0007,FDA,FDA-2017-P-7033,Response Letter from FDA CDER to Jubilant Generics Limited,Other,Approval,2023-04-19T04:00:00Z,2023,4,2023-04-19T04:00:00Z,,2023-04-19T20:15:12Z,,0,0,090000648595eec0
FDA-2017-P-7033-0004,FDA,FDA-2017-P-7033,Exhibit 2 RLD Label re Citizen Petition from Jubliant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:51:33Z,,0,0,0900006482d84da8
FDA-2017-P-7033-0006,FDA,FDA-2017-P-7033,Exhibit 4 Oxetol Dosage & Drug Information re Citizen Petition from Jubliant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:51:56Z,,0,0,0900006482d84daa
FDA-2017-P-7033-0001,FDA,FDA-2017-P-7033,Citizen Petition from Jubliant Generics Limited,Other,Citizen Petition,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-06-28T03:59:59Z,2018-01-02T16:50:17Z,,0,0,0900006482d84d79
FDA-2017-P-7033-0002,FDA,FDA-2017-P-7033,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2018-01-02T16:50:45Z,,0,0,0900006482d84da4
FDA-2017-P-7033-0003,FDA,FDA-2017-P-7033,Exhibit 1 Orange Book Listing re Citizen Petition from Jubliant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:51:21Z,,0,0,0900006482d84da7
FDA-2017-P-7033-0005,FDA,FDA-2017-P-7033,Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubliant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:51:45Z,,0,0,0900006482d84da9